{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:57:37Z","timestamp":1767664657286,"version":"3.37.3"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nanjing Scientific and Technological Development Program","award":["201503049"],"award-info":[{"award-number":["201503049"]}]},{"name":"Nanjing Medical Science and Technique Development Fund","award":["ZKX13045"],"award-info":[{"award-number":["ZKX13045"]}]},{"DOI":"10.13039\/501100013059","name":"Jiangsu Provincial Medical Youth Talent","doi-asserted-by":"publisher","award":["QNRC2016104","QNRC2016535"],"award-info":[{"award-number":["QNRC2016104","QNRC2016535"]}],"id":[{"id":"10.13039\/501100013059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20181489"],"award-info":[{"award-number":["BK20181489"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.biopha.2019.109420","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T21:55:27Z","timestamp":1568670927000},"page":"109420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo"],"prefix":"10.1016","volume":"119","author":[{"given":"Zhengna","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2015","series-title":"Global Cancer Statistics, 2012","author":"Torre","key":"10.1016\/j.biopha.2019.109420_bib0005"},{"issue":"7","key":"10.1016\/j.biopha.2019.109420_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133081","article-title":"BAI1-associated protein 2-Like 1 (BAIAP2L1) is a potential biomarker in ovarian cancer","volume":"10","author":"Chao","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2019.109420_bib0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.biopha.2019.109420_bib0020","first-page":"542","article-title":"Ovarian Cancer survival in Missouri, 1996-2014","volume":"115","author":"Yoshida","year":"2018","journal-title":"Mol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2019.109420_bib0025","first-page":"6687","article-title":"Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.biopha.2019.109420_bib0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/cancers2010088","article-title":"Targeted therapies in epithelial ovarian cancer","volume":"2","author":"Dean","year":"2010","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.biopha.2019.109420_bib0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2019.109420_bib0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ijc.2910600526","article-title":"Kinetics of cisplatin-induced apoptosis in murine mammary and ovarian adenocarcinomas","volume":"60","author":"Meyn","year":"1995","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2019.109420_bib0045","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1535-7163.MCT-11-0725","article-title":"A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo","volume":"11","author":"Chen","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.biopha.2019.109420_bib0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10549-012-2341-9","article-title":"Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen","volume":"137","author":"Yardley","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.biopha.2019.109420_bib0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/1078-0432.CCR-10-1791","article-title":"Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer","volume":"17","author":"Jubb","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2019.109420_bib0060","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1158\/1535-7163.MCT-10-0338","article-title":"Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells","volume":"9","author":"Chang","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.biopha.2019.109420_bib0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI83535","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation","volume":"126","author":"Yu","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.biopha.2019.109420_bib0070","article-title":"An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors","volume":"6","author":"Gohil","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2019.109420_bib0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12872-018-0933-y","article-title":"Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target","volume":"18","author":"Heliste","year":"2018","journal-title":"BMC Cardiovasc. Disord."},{"issue":"11","key":"10.1016\/j.biopha.2019.109420_bib0080","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tcb.2008.08.006","article-title":"Ror receptor tyrosine kinases: orphans no more","volume":"18","author":"Green","year":"2008","journal-title":"Trends Cell Biol."},{"issue":"Pt 8","key":"10.1016\/j.biopha.2019.109420_bib0085","first-page":"2017","article-title":"Ror family receptor tyrosine kinases regulate the maintenance of neural progenitor cells in the developing neocortex","volume":"125","author":"Endo","year":"2012","journal-title":"J. Cell. Sci."},{"issue":"Pt 2","key":"10.1016\/j.biopha.2019.109420_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1242\/jcs.01622","article-title":"Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2","volume":"118","author":"Paganoni","year":"2005","journal-title":"J. Cell. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2019.109420_bib0095","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2-1\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2019.109420_bib0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2014.07.005","article-title":"The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy","volume":"29","author":"Hojjat-Farsangi","year":"2014","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.biopha.2019.109420_bib0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/10428194.2012.731599","article-title":"Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies","volume":"54","author":"Daneshmanesh","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.biopha.2019.109420_bib0110","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2019.109420_bib0115","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.biopha.2019.109420_bib0120","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-12-3832","article-title":"Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis","volume":"73","author":"Cui","year":"2013","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2019.109420_bib0125","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-10-2662","article-title":"Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis","volume":"71","author":"Gentile","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2019.109420_bib0130","first-page":"5087","article-title":"ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer","volume":"18","author":"Xu","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2019.109420_bib0135","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ijc.23587","article-title":"Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy","volume":"123","author":"Daneshmanesh","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2019.109420_bib0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fonc.2012.00034","article-title":"ROR1 and ROR2 in human malignancies: potentials for targeted therapy","volume":"2","author":"Rebagay","year":"2012","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2019.109420_bib0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061167","article-title":"Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells","volume":"8","author":"Hojjat-Farsangi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2019.109420_bib0150","doi-asserted-by":"crossref","first-page":"36447","DOI":"10.1038\/srep36447","article-title":"ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2019.109420_bib0155","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/leu.2011.362","article-title":"Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells","volume":"26","author":"Daneshmanesh","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2019.109420_bib0160","article-title":"Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells","author":"Hasan","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2019.109420_bib0165","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.biopha.2019.109420_bib0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3892\/ijo.2015.3241","article-title":"miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer","volume":"48","author":"Tan","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2019.109420_bib0175","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/srep05811","article-title":"ROR1 expression correlated with poor clinical outcome in human ovarian cancer","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"issue":"55","key":"10.1016\/j.biopha.2019.109420_bib0180","doi-asserted-by":"crossref","first-page":"94210","DOI":"10.18632\/oncotarget.21618","article-title":"Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells","volume":"8","author":"Yin","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.biopha.2019.109420_bib0185","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbrc.2019.03.028","article-title":"A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo","volume":"512","author":"Liu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2019.109420_bib0190","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13256-016-0994-4","article-title":"The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report","volume":"10","author":"Hirai","year":"2016","journal-title":"J. Med. Case Rep."},{"issue":"3","key":"10.1016\/j.biopha.2019.109420_bib0195","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/biof.1498","article-title":"ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K\/Akt\/mTOR signaling pathway","volume":"45","author":"Mao","year":"2019","journal-title":"Biofactors"},{"issue":"10","key":"10.1016\/j.biopha.2019.109420_bib0200","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/s41375-018-0113-1","article-title":"First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells","volume":"32","author":"Hojjat-Farsangi","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biopha.2019.109420_bib0205","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1073\/pnas.1816262116","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2019.109420_bib0210","article-title":"Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer","author":"Liu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2019.109420_bib0215","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev.iy.12.040194.002245","article-title":"Making antibodies by phage display technology","volume":"12","author":"Winter","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biopha.2019.109420_bib0220","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3389\/fimmu.2019.01230","article-title":"The molecular basis of human IgG-Mediated enhancement of C4b-Binding protein recruitment to group a Streptococcus","volume":"10","author":"Ermert","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2019.109420_bib0225","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ijc.28451","article-title":"A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo","volume":"134","author":"Lin","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2019.109420_bib0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059639","article-title":"Apoptosis through Bcl-2\/Bax and cleaved caspase up-regulation in melanoma treated by boron neutron capture therapy","volume":"8","author":"Faiao-Flores","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2019.109420_bib0235","doi-asserted-by":"crossref","first-page":"e127092","DOI":"10.1371\/journal.pone.0127092","article-title":"Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K\/AKT\/mTOR signaling pathway in lung adenocarcinoma","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219333943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219333943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:07:07Z","timestamp":1731427627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219333943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":47,"alternative-id":["S0753332219333943"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109420","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"109420"}}